GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Taiwan Advanced Nanotech 6797.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

9.74

-2.60%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Taiwan Advanced Nanotech

Its shares trade on Taipei Exchange under the ticker 6797.TWO. It has been listed since 5 November 2020. In the fiscal year to 31 December 2025, it reported revenue of TWD 154.4m and a net loss of TWD 226.6m. At that date it held total assets of TWD 1.25bn and shareholders' equity of TWD 772.4m.

Taiwan Advanced Nanotech, Inc. engages in the design and manufacture of nucleic acid purification products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2020-11-05. The main products include SLA series, Maelstrom series and LH series instruments for DNA/RNA nucleic acid extraction; virus nucleic acid extraction reagent 665 series reagents; blood nucleic acid extraction reagent 611/61E series reagents and tissue nucleic acid extraction reagent 6T2/6K2 series reagents. Products are sold to Taiwan, South Korea, China and other countries.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
5 Nov 2020
Website
tanbead.com ↗

Leadership

Pay as last reported

  • Ms. Jiyun ZhangChairman of the Board, since 2017
  • Mr. Raman ChienGeneral Manager, Director, since 2004
  • Mr. Steve ChuDeputy General Manager
  • Zhiwei ZhangHead of Finance & Accounting
  • Ms. Hsiu-Miao HuangDirector
  • Ms. Xiaomei LiIndependent Director
  • Jiahao SuIndependent Director
  • Weizheng SuIndependent Director
  • Mr. Fengyu ZhengIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company designs and manufactures nucleic acid purification products.
  • It operates from a headquarters in Taoyuan, Taiwan.
  • It has been publicly traded since November 2020.

Weaknesses

  • The source description is explicitly treated as untrusted facts.
  • Specific financial data points are not provided in the text.
  • Market share figures are absent from the available information.

Opportunities

  • It sells products to Taiwan, South Korea, and China.
  • The industry sector is defined as Health Care.
  • Global demand for nucleic acid extraction tools exists.

Threats

  • Reliance on untrusted source descriptions poses accuracy risks.
  • Competitors in the health care sector are not detailed.
  • Regulatory changes in international markets are unknown.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.